

TARGETED GENETICS CORP /WA/

Form 8-K

April 06, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 31, 2004

**Targeted Genetics Corporation**

---

(Exact name of registrant as specified in charter)

Washington

0-23930

91-1549568

---

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington

98101

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (206) 623-7612

Not Applicable

(Former name or former address, if changed since last report)

---

**Item 5. Other Events.**

On April 6, 2004, Targeted Genetics Corporation issued a press release announcing an agreement with Elan Corporation plc that formally concludes the collaboration between the companies through the joint venture, Emerald Gene Systems, Ltd., or the Termination Agreement. A copy of the press release is furnished as Exhibit 99.1 and is incorporated into this current report by reference. A copy of the Termination Agreement is furnished as Exhibit 99.2 and is incorporated into this current report by reference.

**Item 7. Exhibits.**

- (a) Financial statements of business acquired.

Not applicable.

- (b) Pro forma financial information.

Not applicable.

- (c) Exhibits.

**Exhibit  
No.**

**Description**

99.1	Press Release of Targeted Genetics Corporation dated April 6, 2004
99.2	Termination Agreement, dated March 31, 2004, among Targeted Genetics, Elan Corporation PLC, Elan Pharma International Limited, Elan International Services, Ltd. and Emerald Gene Systems, Ltd.*

\* Portions of this exhibit have been omitted based on an application for confidential treatment filed with the SEC. The omitted portions of the exhibit have been filed separately with the SEC.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TARGETED GENETICS CORPORATION

By: /s/ Todd E. Simpson

Todd E. Simpson  
Vice President, Finance and  
Administration and Chief Financial  
Officer, Secretary and Treasurer  
(Principal Financial and Accounting  
Officer)

Date: April 6, 2004



EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Targeted Genetics Corporation dated April 6, 2004
99.2	Termination Agreement, dated March 31, 2004, among Targeted Genetics, Elan Corporation PLC, Elan Pharma International Limited, Elan International Services, Ltd. and Emerald Gene Systems, Ltd.*

\* Portions of this exhibit have been omitted based on an application for confidential treatment filed with the SEC. The omitted portions of the exhibit have been filed separately with the SEC.